October 30th 2024
A new drug application for a 3-month depot formulation of leuprolide mesylate has been submitted to the FDA.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Dr. Charles Ryan on Abiraterone Acetate in Elderly mCRPC Patients
May 18th 2016Charles Ryan, MD, Professor of Clinical Medicine and Urology, Department of Medicine, Program Leader, Genitourinary Medical Oncology at the Helen Diller Family Comprehensive Cancer at the Univeristy of California San Francisco, discusses abiraterone acetate in elderly chemotherapy naive patients with metastatic castration resistant prostate cancer (mCRPC).
Watch
New Analysis of Screening Data Questions Current USPSTF PSA Recommendations
May 11th 2016A high rate of PSA testing in the control arm of the Prostate, Lung, Colorectal, and Ovary screening trial made meaningful comparisons with the intervention group impossible, according to a new analysis of data from the landmark trial.
Read More
Dr. Oliver Sartor on Considerations, Controversy With PSA Testing in Prostate Cancer
May 11th 2016A. Oliver Sartor, MD, Medical Director of Tulane Cancer Center, explains why primary care physicians and oncologists/urologists have differences of opinion when it comes to prostate-specific antigen (PSA) testing.
Watch
Abiraterone Effective, Tolerable in Difficult-to-Treat mCRPC Populations
May 11th 2016Abiraterone acetate in combination with low-dose prednisone showed a low overall incidence of corticosteroid-associated adverse events that were not significantly different compared with prednisone alone for patients with metastatic castration-resistant prostate cancer.
Read More
Dr. Neal Shore on Lack of Corticosteroid-Associated Adverse Events with Prednisone Plus Abiraterone
May 10th 2016Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).
Watch
Steroid Use With Abiraterone Offers Multidimensional Benefits to Patients With mCRPC
April 21st 2016For decades, the standard of care for men with advanced prostate cancer has been the depletion or inhibition of androgens. While androgen-deprivation therapy (ADT) often results in temporary tumor regression or symptom relief in some patients, disease progression ultimately occurs over time.
Read More
Experts Discuss Treatment Sequencing Strategies in CRPC
April 21st 2016As the treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) continues to evolve, optimal strategies are becoming more apparent on how to best sequence the multitude of novel therapies that have been approved in the past decade.
Read More
Analysis of Real-World Data for Next-Generation Antiandrogen Therapies
April 21st 2016Since 2010, several novel therapies have been approved for use in metastatic castration-resistant prostate cancer (mCRPC). Although they have expanded the therapeutic repertoire for clinicians, they also bring a new set of challenges for the optimal clinical management of patients with mCRPC.
Read More
Guidelines Evolving for the Treatment of Bone Metastases in CRPC
April 19th 2016Androgen deprivation therapy (ADT) has been the standard of care for patients with advanced prostate cancer; however, a majority of patients on hormonal therapy become unresponsive to treatment after an initial response.
Read More
Preventing and Treating Bone Metastases in mCRPC
April 19th 2016Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.
Read More
Bone Metastases a Major Concern in Prostate Cancer
April 19th 2016Circulating tumor cells (CTCs) have been recognized as a potential source of prostate cancer seeding to distant metastatic sites (typically bone) for over a century, and with ongoing improvements in isolation and characterization methodology, CTCs are now being more rigorously investigated as potential predictive biomarkers in men with mCRPC.
Read More
Abiraterone Acetate Plus Prednisone Demonstrates OS Benefit in Prostate Cancer
March 18th 2016An abiraterone acetate (Zytiga) plus prednisone combination showcased an 11.8-month improvement in overall survival (OS) when compared with prednisone and placebo in less advanced, chemotherapy-naive metastatic castration-resistant prostate cancer.
Read More
FDA to Review sNDA for Enzalutamide in Metastatic Prostate Cancer
February 24th 2016The FDA has accepted a supplemental new drug application for a capsulated form of enzalutamide for review in patients with metastatic castration-resistant prostate cancer. This application includes findings from the head-to-head studies, TERRAIN and STRIVE.
Read More